Table 1 Comparing three main subtypes of NKT cells [8, 220, 221]
From: CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Special | Type 1 NKT | Type 2 NKT | NKT like cell |
|---|---|---|---|
CD1d dependent | Yes | Yes | No |
α-GalCer reactive | Yes | No | No |
TCRa chain | Va14-ja18(mice), va24 ja18(human) | Diverse, but some vas3.2-ja9, Va8(mice) | Diverse |
NK1.1 or CD161 | Positive (resting mature) | Positive and negative | Positive |
Restriction | CD1d | CD1d | MHC |
Subset | CD4+DN(mice) CD4+CD8+DN(human) | CD4+ and DN | CD4+, DN, and CD8+ |
IL-4 production | Yes | Yes | No |
IFNγ production | Yes | Yes | Yes |
Development requirements | IL-15 | Not Established | Not Established |
Tissue location | Liver, spleen, intestine, and pulmonary mucosa | Liver and spleen | Liver, spleen, and bone marrow |
TCRB chain | VB2, VB7, VB8.2 (mice) VB11 (human) | Diverse, but some VB8.2 (mice) | Diverse |